INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of
business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan
language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting
certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document
[Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may
differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan
document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit
plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage
mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific
instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable
laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular
situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for
treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support
medical necessity and other coverage determinations.

Coverage Policy
Coverage of carotid intima-media thickness (CIMT) testing may be governed by state and/or federal mandates.

Carotid intima-media thickness (CIMT) testing for any indication including the evaluation of atherosclerotic burden or coronary heart disease risk factor assessment is considered experimental, investigational or unproven.

Overview
This Coverage Policy addresses carotid intima-media thickness (CIMT) testing.

General Background
Measurement of the carotid intima-media thickness (CIMT) is a noninvasive test, where the lining of the carotid arteries is measured with the use of B-mode ultrasound. The intima is the innermost layer of the artery, and the media is the middle layer of the artery. Carotid ultrasound has been routinely used for evaluation of ischemic cerebrovascular signs and symptoms. In the utilization of carotid ultrasound in the context of risk stratification, the intima-media thickness is measured for the objective of detecting preclinical or subclinical cardiovascular disease. Measurement of the CIMT is considered to be a surrogate marker for the measurement of atherosclerosis, which correlates with the presence of coronary atherosclerosis. This has led to the theory that it
may represent an independent marker, separate from the traditional risk factors for cardiovascular disease and stroke. The major independent risk factors are cigarette smoking, elevated blood pressure, elevated serum total and LDL cholesterol, low serum HDL cholesterol, diabetes mellitus, and advancing age. Additional risk factors include obesity, family history of premature coronary heart disease (CHD), and physical inactivity (Pearson, 2000). It is not clear if the measurement of CIMT provides benefit above traditional risk factors or if treatment guided by this test has an effect on clinical outcomes.

The wall thickness can be measured at a single site, such as the far wall of common carotid artery or at several sites including near and far walls of the left and right common carotid arteries, bifurcation, and internal carotid artery (Crouse, 2006). CIMT has been widely used in research as an outcome measurement in studies, including tests involving the following (Simon and Levenson, 2002):

- testing the value of new or emerging risk factors by means of observational or epidemiological studies in groups of patients or in general populations
- evaluating effects of risk factor modifications by various drugs on progression of early arterial wall alteration in therapeutic trials

Disadvantages that have been identified to be associated with the use of this testing procedure include (Nissen, 2004):

- A high level of technical expertise is needed for precise quantification. In particular, this is needed when the measurement is used in for multicenter studies, since the precision of the studies depends upon the measurement of extremely small differences in thickness.
- There is an incomplete standardization of equipment, with various devices and frequencies employed at different centers.

Difficulties that have been identified with CIMT testing include: poor image quality, drifting, improper machine settings and difficult patient anatomy (e.g., high bifurcations of the carotid artery and deep vessels) (Mitchell, et al., 2004). At this time, there is a lack of standardization of measurement and imaging protocols. It is not clear whether generalized IMT or focal plaque formation is of more importance (Mancini, et al., 2004). The literature indicates that there are gender- and age-related differences with IMT. A definition of what is considered expected normal limits that take into account these differences has not been established. It is not evident from the literature that CIMT is able to improve on risk prediction above what is provided by utilization of traditional risk factors or the effect of these measurements on patient outcomes.

**Literature Review**

**Systematic reviews:** van den Oord et al. (2013) reported on a systematic review and meta-analysis of the published evidence on the association of CIMT with future cardiovascular events and its additional value to traditional cardiovascular risk prediction models. The association of CIMT with future cardiovascular events and the additional value of CIMT were calculated using random effects analysis. The review included 15 articles that provided sufficient data for the meta-analysis. A one standard deviation (SD) increase in CIMT was predictive for myocardial infarction (HR 1.26, 95% CI 1.20 e1.31) and for stroke (HR 1.31, 95% CI 1.26e1.36). A 0.1 mm increase in CIMT was predictive for myocardial infarction (HR 1.15, 95% CI 1.12e1.18) and for stroke (HR 1.17, 95% CI 1.15e1.21). It was found that the overall performance of risk prediction models did not significantly increase after addition of CIMT data. The areas under the curve increased from 0.726 to 0.729 (p ¼ 0.8). The authors concluded that CIMT as measured by B-mode ultrasound is associated with future cardiovascular events; however, the addition of CIMT to traditional cardiovascular risk prediction models does not lead to a statistically significant increase in performance of those models.

Den Ruijter et al. (2012) conducted a meta-analysis to determine whether common CIMT has added value in 10-year risk prediction of first-time myocardial infarctions or strokes, above that of the Framingham Risk Score. The review included 14 population-based cohorts with data for 45,828 individuals. The studies included participants were drawn from the general population, common CIMT was measured at baseline, and individuals were followed up for first-time myocardial infarction or stroke. Individual data were combined into one data set and an individual participant data meta-analysis was performed on individuals without existing cardiovascular disease. During a median follow-up of 11 years, 4,007 first-time myocardial infarctions or strokes occurred. The risk
factors of the Framingham Risk Score were refitted and then the model with common CIMT measurements was extended to estimate the absolute 10-year risks to develop a first-time myocardial infarction or stroke in both models. The added value of common CIMT measurements to the Framingham Risk Score in the general population was found to be minor (0.8% were correctly reclassified). In individuals at intermediate risk, the added value was 3.2% in men and 3.9% in women. The authors concluded that the addition of common CIMT measurements to the Framingham Risk Score was associated with small improvement in 10-year risk prediction of first-time myocardial infarction or stroke, but this improvement is unlikely to be of clinical importance. The findings of this study indicate that there is little clinical utility of using CIMT for cardiac risk assessment.

Lorenz, et al. (2012) conducted a meta-analysis to test the association between changes in CIMT and cardiovascular risk (PROG-IMT collaborative project). The review included 16 studies with 36,984 participants. The review identified general population cohort studies that assessed CIMT at least twice and followed up with participants for myocardial infarction, stroke, or death. During a mean follow-up of seven years, 1,519 myocardial infarctions, 1,339 strokes, and 2,028 combined endpoints (myocardial infarction, stroke, vascular death) occurred. Individual participant data meta-analysis was performed. After excluding individuals with previous myocardial infarction or stroke, the association was assessed between CIMT progression and the risk of cardiovascular events (myocardial infarction, stroke, vascular death, or a combination of these) for each study with Cox regression. Yearly CIMT progression was derived from two ultrasound visits 2–7 years apart. No evidence of an association between individual CIMT progression and the risk of subsequent cardiovascular events, irrespective of definition of CIMT, endpoint, and adjustment. The authors strongly advocate further validations and improvements of ultrasound protocols. The authors concluded that the association between CIMT progression assessed from two ultrasound scans and cardiovascular risk in the general population remains unproven. Further studies are needed to determine how the association between CIMT progression and cardiovascular risk and the assessment of CIMT will affect health outcomes.

Costanzo et al. (2010) reported on a systematic review conducted with the aim to assess, using a meta-regression analysis of randomized trials whether reduced progression or regression of IMT is associated with a reduced incidence of major cardiovascular events in subjects at intermediate to high cardiovascular risk. The review included 41 trials with 18,307 participants that assessed carotid IMT at baseline, at the end of follow-up, and reporting clinical end points. The influence of baseline patients’ characteristics, cardiovascular risk profile, IMT at baseline, follow-up, and quality of the trials was also examined. Although there was a significant reduction in coronary heart disease (CHD) and cerebrovascular (CBV) events, and all-cause death induced by active treatments (for CHD events, odds ratio [OR]: 0.82, 95% confidence interval [CI]: 0.69 to 0.96, p=0.02; for CBV events, OR: 0.71, 95% CI: 0.51 to 1.00, p=0.05; and for all-cause death, OR: 0.71, 95% CI: 0.53 to 0.96, p=0.03), there was no significant relationship between IMT regression and CHD events, CBV events, and all-cause death. It was also noted that subjects’ baseline characteristics, cardiovascular risk profile, IMT at baseline, follow-up, and quality of the trials did not significantly influence the association between IMT changes and clinical outcomes. The authors concluded that the regression or slowed progression of CIMT, induced by cardiovascular drug therapies do not reflect reduction in cardiovascular events.

A systematic evidence synthesis of nine novel risk factors for CHD, including CIMT, for intermediate-risk persons was conducted for the US Preventive Services Task Force (USPSTF) (Helfand, et al., 2009). Regarding CIMT, the review noted that:

- Six population-based longitudinal studies (five cohorts) in asymptomatic persons followed for the development of CHD
- The reports from two of the five studies had no adjustment for other risk factors and were rated poor-quality
- CIMT persisted as an independent risk factor in the three cohorts after full or partial adjustment for Framingham risk factors. The relative risks or hazard ratios ranged from 1.19–3.80 for various degrees of CIMT (mm) or a composite score of CIMT or plaque.
- No data was identified regarding the prevalence of high CIMT among asymptomatic intermediate-risk individuals
- Regarding future research recommendations it was noted, “Epidemiologic cohorts that have measured carotid IMT should measure the impact of carotid IMT on prediction of CHD events among intermediate-risk individuals and on reclassification of these individuals. It is highly plausible that intervention directed
toward modification of traditional risk factors in individuals with increased carotid IMT might reduce the risk of subsequent CHD. Randomized controlled trials are needed to evaluate this hypothesis.”

Wald et al. (2009) reported on a meta-analysis of studies that assessed the screening performance of CIMT and carotid plaque in identification of individuals with CHD. The review included 18 case-control and cohort studies that involved 2,920 individuals with CHD and 41,941 without. An assessment of screening performance (detection rates [DRs] for specified false positive rates [FPRs]) was carried out from the relative Gaussian distributions of IMT among individuals with and without CHD and from the proportion of affected and unaffected individuals with plaque. Findings included: for plaque that the DR was 62% for an FPR of 30%; and for IMT, the DR was 65% for the same 30% FPR. The authors concluded that neither carotid plaque nor IMT has a CHD screening performance that is sufficiently discriminatory between affected and unaffected individuals to be considered a worthwhile screening test.

Baldassarre et al. (2008) conducted a meta-analysis of 107 studies addressing the association between CIMT and soluble markers and to investigate whether these observed inconsistencies could be explained by the characteristics of the patients included in different studies (e.g., the prevalence of atherosclerotic disease, gender, age, or occurrence of specific vascular risk factors [VRFs]). Regardless of the marked heterogeneity of results presented in the literature, the meta-analysis demonstrated that studies showing positive associations between CIMT and plasma levels of C-reactive protein (CRP) or fibrinogen are in the majority. The data regarding the relationships between CIMT and other soluble markers are by contrast noted to be scanty, contradictory, or unconfirmed by multivariate (as opposed to univariate) analyses, and the freedom from publication bias here cannot be assured. Gender, noninsulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia appeared to influence the association between CIMT and CRP. Blood pressure and hypercholesterolemia appeared to influence the association between CIMT and fibrinogen. The heterogeneity in ultrasound methodologies and in statistical approach limited comparability between studies.

Lorenz et al. (2007) conducted a systematic review of the literature to provide an overview of the relevant studies, critically appraise the methods used and, where possible, to perform a meta-analysis to gain more robust estimates of the predictive value of increased IMT to predict future clinical cardiovascular end points. The review included eight observational studies with general population based samples for which CIMT was measured and follow-up for clinical end points were provided. The studies represented 37,197 subjects followed for a mean of 5.5 years. Major sources of heterogeneity were age distribution, carotid segment definition and IMT measurement protocol. The review found that CIMT is a strong predictor of future vascular events. In addition, it was noted that the relative risk per IMT difference is slightly higher for the end point of stroke than for MI. The review also noted heterogeneity between the studies regarding the details of the ultrasound protocols. These details included: the precise definitions of the carotid segments investigated, the use of mean or maximal IMT, the measurement of near and far wall or IMT, and whether IMT is measured on one side or both sides. It is recommended that in future studies of IMT, ultrasound protocols should be aligned with published studies. It appears that data for younger individuals is limited, and additional studies are required.

Studies: Jeevarethinam et al. (2015) reported on a study that examined whether increased carotid intima–media thickness (cIMT) and prevalence of carotid plaque (CP) are predictive of prevalence and severity of coronary atherosclerosis. The retrospective study included 150 consecutive patients with no history of coronary artery disease (CAD), who underwent both carotid ultrasound and computed tomographic coronary angiography. The mean cIMT was higher in patients with CAD than in those without CAD (0.76 vs 0.66 mm, P<.003). Backward selection analysis demonstrated higher mean cIMT measurement correlated well with prevalence of any coronary plaque (P=.03) and obstructive coronary plaque disease (P=.05), whereas presence of CP was a good predictor of both obstructive (>50% stenosis P=.003) and any coronary plaque (P=.003). This study was limited by small sample size, predominantly middle-aged males and the retrospective nature of the study.

Polak et al. (2011) conducted a study that examined if the intima–media thickness of the walls of the common carotid artery and internal carotid artery could add to the Framingham risk score for predicting cardiovascular events. The mean intima–media thickness of the common carotid artery and the maximum intima–media thickness of the internal carotid artery were measured in 2,965 members of the Framingham Offspring Study cohort. Cardiovascular disease outcomes were evaluated for an average follow-up of 7.2 years. Multivariable Cox proportional hazards models were generated for intima–media thickness and risk factors. Reclassification
was performed of cardiovascular disease on the basis of the 8-year Framingham risk score category (low, intermediate, or high) after adding intima–media thickness values. A total of 296 participants had a cardiovascular event with the risk factors of the Framingham risk score predicting these events, with a C statistic of 0.748 (95% confidence interval [CI], 0.719–0.776). The adjusted hazard ratio for cardiovascular disease with a 1-SD increase in the mean intima–media thickness of the common carotid artery was 1.13 (95% CI, 1.02–1.24), with a nonsignificant change in the C statistic of 0.003 (95% CI, 0.000–0.007); the corresponding hazard ratio for the maximum intima–media thickness of the internal carotid artery was 1.21 (95% CI, 1.13–1.29), with a modest increase in the C statistic of 0.009 (95% CI, 0.003–0.016). The net reclassification index increased significantly after addition of intima–media thickness of the internal carotid artery (7.6%, p<0.001) but not intima–media thickness of the common carotid artery (0.0%, P = 0.99). With the presence of plaque, defined as intima–media thickness of the internal carotid artery of more than 1.5 mm, the net reclassification index was 7.3% (p=0.01), with an increase in the C statistic of 0.014 (95% CI, 0.003–0.025). The authors concluded that the maximum internal and mean common carotid-artery intima–media thicknesses both predict cardiovascular outcomes, but only the maximum intima–media thickness of (and presence of plaque in) the internal carotid artery had a modest effect of improving the classification of risk of cardiovascular disease in this cohort. Limitations of the study included that the population only included white race and the results may not be applicable to other races or ethnic groups; the follow-up period was 7.2-years up period, which is shorter than the 10-year period for which the Framingham risk score is calculated; and a single experienced and supervised sonographer to was used to obtain high-quality measurements during carotid artery ultrasonography, which may affect the implementation of our findings in primary prevention.

There are several observational, longitudinal studies published that demonstrate a correlation between CIMT measurement and established risk factors for heart disease (Villines, et al., 2017; Geisel, et al., 2017; Nambi, et al., 2010; Kathiresan, et al., 2007; Amato, et al., 2007; O'Leary, et al., 1999; Hodis, et al., 1998; Bots, et al., 1997; Chambless, et al., 1997).

Although there appears to be an association with established risk factors for heart disease, cohort and case-control studies have not demonstrated that use of this test results in a substantial increase in predictive value when utilized as a screening tool in addition to established risk factors or if patient treatment guided by CIMT improves cardiovascular outcomes (Bot, et al., 2014; Jain, et al., 2011; Folsom et al., 2008; Baldassare, et al., 2007; Kitagawa, et al., 2007; Kanawar, et al., 2007; Gepner, et al., 2006; Iglesias del Sol, et al., 2001).

Lorenz, et al. (2010) published results of a ten-year follow-up of a cohort of 4,904 patients without pre-existing vascular disease in the Carotid Atherosclerosis Progression Study (CAPS). The usefulness of CIMT in individual risk prediction beyond the Framingham and the SCORE models was investigated. The authors found that while CIMT was predictive for cardiovascular endpoints, it did not consistently improve the risk classification of individuals.

Professional Societies/Organizations
American Association of Clinical Endocrinologists (AACE): the AACE published guidelines for management of dyslipidemia and prevention of atherosclerosis (Jellinger, et al., 2012). The guidelines include the following recommendation: Noninvasive measures of atherosclerosis such as carotid intima media thickness and coronary artery calcification should not be performed routinely, but may be used in certain clinical situations as adjuncts to standard cardiovascular disease risk factors in an attempt to refine risk stratification and the need for more aggressive preventive strategies.

(Assessment Rating: Grade 4 - No evidence [theory, opinion, consensus, review, or preclinical study])

American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Practice Guidelines: The ACC/AHA published updated 2013 ACC/AHA guidelines, in collaboration with National Heart, Lung, and Blood Institute (NHLBI) on the assessment of cardiovascular risk (Goff, et al., 2014). The guidelines include the following regarding CIMT:

CIMT is not recommended for routine measurement in clinical practice for risk assessment for a first ASCVD event.
NHLBI grade: (Grade N*, No Recommendation For or Against)
ACC/AHA Class III*: No Benefit, LOE B*
Based on new evidence reviewed during ACC/AHA update of the evidence.

* Grade N: No recommendation for or against
There is insufficient evidence or evidence is unclear or conflicting.)
Net benefit is unclear. Balance of benefits and harms cannot be determined because of no evidence, insufficient evidence, unclear evidence, or conflicting evidence, and the Work Group thought no recommendation should be made. Further research is recommended in this area.

Class III/LOE B: recommendation that procedure or treatment is not useful/effective and may be harmful; evidence from single randomized trial or nonrandomized studies

American College of Preventive Medicine (ACPM): the ACPM published position statement for atherosclerotic cardiovascular disease screening in adults (Lim, et al., 2011). The statement notes that the ACPM "recommends CHD risk assessment using the FRS [Framingham Risk Score] to guide risk-based therapy. ACPM does not recommend routine screening of the general adult population using electrocardiogram, exercise-stress testing, computed tomography scanning, ankle-brachial index, carotid intima medial thickness, or emerging risk factors, including high-sensitivity C-reactive protein (hs-CRP)."

American Diabetes Association and American College of Cardiology Foundation: A consensus statement from these two organizations was published regarding lipoprotein management in patients with cardiometabolic risk (Brunzell, et al., 2008). The report included the following statements regarding CIMT measurement:

- The presence of so-called subclinical vascular disease may be determined by measuring coronary calcification, carotid intima-media thickness, or the ankle-brachial index. Patients with documented subclinical atherosclerosis are at increased cardiovascular disease risk and may be considered candidates for more aggressive therapy
- Whether such tests improve prediction or clinical decision making in patients with diabetes or cardiometabolic risk is unclear.

American Society of Echocardiography (ASE) American and the Society of Vascular Medicine and Biology: A report published in 2006 by these two organizations, Clinical Application of Noninvasive Vascular Ultrasound in Cardiovascular Risk Stratification, notes that numerous carotid artery imaging protocols have been proposed. The protocols and methodological aspects are reviewed in the report. The report notes that protocols may vary in the number of segments in which IMT is measured, whether the near wall is measured in addition to the far wall, and whether IMT measurements are derived from B-mode or M-mode ultrasound images (Roman, et al., 2006).

In 2008, these two organizations published a consensus statement—Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine (Stein, et al., 2008). In order to address the issues of standardization and assist in improving the availability of experienced clinical laboratories that can perform high-quality CIMT studies, the societies have provided recommendations for carotid ultrasound scanning protocol. It is noted that since a randomized controlled trial studying the effectiveness of carotid ultrasound imaging as a tool to modify preventive therapies and improve cardiovascular disease outcomes has not been performed, the clinical practice recommendations are based on observational data. The guidelines note that additional research is required in order to determine whether improved risk prediction observed with CIMT or carotid plaque imaging translates into improved patient outcomes. The recommendations for performing CIMT include:

- Measuring CIMT and identifying carotid plaque by ultrasound are most useful for refining cardiovascular risk assessment in patients at intermediate cardiovascular risk (i.e., Framingham risk score 6-20% without established coronary heart disease, peripheral arterial disease, cerebrovascular disease, diabetes mellitus or abdominal aortic aneurysm).
- CIMT assessment and carotid plaque detection may also be considered in the following situations:
- patients with family history of premature cardiovascular disease in a first degree relative (i.e., men <55 years old, women <65 years old)
- individuals younger than 60 years old with severe abnormalities in a single risk factor (e.g., genetic dyslipidemia) who otherwise would not be candidates for pharmacotherapy
- women younger than 60 years old with at least two cardiovascular risk factors

- Imaging should not be performed in the following situations:
  - with established atherosclerotic vascular disease
  - if the results would not be expected to alter therapy

- Serial studies of CIMT to address progression or regression are not recommended.

Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council Cardiovascular Radiology and Intervention, American Heart Association: A consensus statement from these groups was published regarding the role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease (Mieres, et al., 2005). The consensus statement makes the following notations regarding CIMT:

- CIMT is one of several emerging imaging modalities in the detection of subclinical atherosclerotic heart disease in women that has not amassed the wealth of evidence that would clearly define the role in the clinical evaluation of women with suspected atherosclerotic heart disease.
- The advantages of CIMT include the wide availability of ultrasound technology, absence of ionizing radiation or incidental scan findings and well-validated nature of the test results.
- The limitations of the test include the lack of accepted technical standards for IMT testing and the absence of published population distributions of IMT. Further precise documentation of what defines an abnormal level of IMT and measurement guidelines are needed.
- The clinical use of CIMT for risk stratification in asymptomatic women has not been shown to result in improved outcomes.

Mannheim Carotid Intima-Media Thickness Consensus (2004-2006): The Mannheim Consensus was convened to standardize methods used in the measurement of CIMT. The consensus statement notes that, “Although IMT has been suggested to represent an important risk marker, according to the current evidence it does not fulfill the characteristics of an accepted risk factor. Standardized methods recommended in this consensus statement will foster homogenous data collection and analysis. This will help to improve the power of randomized clinical trials incorporating IMT measurements and to facilitate the merging of large databases for meta-analyses.” It is noted that there is no need to “treat IMT values nor to monitor IMT values in individual patients.” (Touboul, et al., 2007)

US Preventive Services Task Force (USPSTF): The USPSTF Recommendation Statement on Using Nontraditional Risk Factors In Coronary Heart Disease Risk Assessment concluded that the current evidence is insufficient to assess the balance of benefits and harms of using the nontraditional risk factors discussed in this statement to screen asymptomatic men and women with no history of CHD to prevent CHD events (USPSTF, October 2009). (Grade: I [Insufficient] Statement, current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.) The nontraditional risk factors included in this recommendation are high-sensitivity C-reactive protein (hs-CRP), ankle–brachial index (ABI), leukocyte count, fasting blood glucose level, periodontal disease, carotid intima–media thickness (carotid IMT), coronary artery calcification (CAC) score on electron-beam computed tomography (EBCT), homocysteine level, and lipoprotein(a) level. (USPSTF, 2009)

Use Outside of the US
European Society of Cardiology (ESC): The ESC published updated guidelines on cardiovascular disease prevention in clinical practice. With regard to CIMT the guidelines note that, “The lack of standardization regarding the definition and measurement of IMT, its high variability and low intra-individual reproducibility have raised concerns. A recent meta-analysis failed to demonstrate any added value of IMT compared to the Framingham Risk Score in predicting future CVD, even in the intermediate risk group. Thus, the systematic use of carotid ultrasound IMT to improve risk assessment is not recommended.” (Piepoli, et al., 2016)
**Coding/Billing Information**

**Note:** 1) This list of codes may not be all-inclusive.

2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Experimental/Investigational/Unproven:**

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>93895</td>
<td>Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral</td>
</tr>
<tr>
<td>0126T</td>
<td>Common carotid intima-media thickness (IMT) study for evaluation of atherosclerotic burden or coronary heart disease risk factor assessment</td>
</tr>
</tbody>
</table>


**References**


